

Accepted as poster #FRI0552 at Annual European Congress of Rheumatology (EULAR) 2018, Amsterdam, Netherlands, June 13-16, 2018

SM04690, A WNT PATHWAY INHIBITOR: ANTI-INFLAMMATORY AND CARTILAGE PROTECTIVE EFFECTS IN PRECLINICAL OA MODELS

Vishal Deshmukh, Timothy Seo, Christopher Swearingen, and Yusuf Yazici

Samumed, LLC, San Diego, USA

Background: Osteoarthritis (OA) is characterized by pain, swelling, and reduced function in the knee joint. Upregulated Wnt signalling drives OA through synovial inflammation, increased subchondral bone, and thinning cartilage.

Objectives: SM04690, a small molecule Wnt pathway inhibitor that demonstrated chondrogenic and anti-inflammatory properties preclinically,¹ was further evaluated to determine its potential to reduce inflammation, protect cartilage, improve joint health, and modify pain in OA.

Methods: Cytokine secretion (IL-6 and TNF- α) from IL-1 β -stimulated and SM04690-treated synovial fibroblasts was measured by ELISA. A single intra-articular injection of SM04690 or vehicle was evaluated in an *in vivo* rat knee monosodium iodoacetate (MIA) OA model. Joint inflammation was evaluated by H&E staining, inflammatory cytokines (IL-1 α , IL-1 β , IL-6, TNF- α and IFN- γ) by qPCR, and cartilage protection by qPCR for matrix metalloproteinases (MMPs). Histological evaluation of cartilage health was performed using OARSI score and thickness by Safranin-O staining. Pain was measured as paw withdrawal threshold using Von Frey apparatus and weight distribution using incapitance meter and analysed using generalized estimating equation regression.

Results: SM04690 dose-dependently inhibited IL-1 β -induced cytokine secretion in synovial fibroblasts (EC_{50} ~ 30 nM; Fig.1). In the rat MIA OA model, compared to vehicle, SM04690 injection reduced visible knee swelling, inflammatory cells, and proinflammatory cytokine and MMP production ($p < 0.05$). SM04690 increased ($p < 0.01$) paw withdrawal threshold from Day 6 and improved weight distribution to the affected limb in treated rats, at multiple timepoints, compared to vehicle (Fig.2). SM04690 increased Safranin-O stained cartilage thickness and decreased OARSI score ($p < 0.05$) compared to vehicle.

Conclusions: In a rat MIA OA model, SM04690 injection reduced inflammation, protease production, and pain, with improved cartilage and joint health, compared to vehicle. Previously demonstrated regenerative effects in nonclinical studies¹, along with anti-inflammatory properties, show SM04690 may improve symptoms and potentially provide disease modification in OA. Clinical studies are ongoing.

References: ¹Deshmukh V et al. *Osteoarthritis Cartilage* 2018;26:18-27.

Figure 1. SM04690 inhibited inflammatory cytokine production in synovial fibroblasts *in vitro*




Figure 2. SM04690 inhibited inflammatory cytokine production and decreased inflammation and pain in the MIA model of OA

